Car T-Cell Therapy

Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, yielded an overall response rate of 97% in 97 heavily pretreated patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

The FDA granted orphan drug designation to CTD401, a chimeric antigen receptor T-cell therapy for the treatment of T-cell acute lymphoblastic leukemia, according to the agent’s manufacturer.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about breakthroughs in therapy that he hopes to see in the future.

More than 80% of patients with relapsed or refractory multiple myeloma remained alive 18 months after receiving a single infusion of ciltacabtagene autoleucel, according to the latest results of a phase 1/phase 2 clinical trial.

Ninety-five percent of patients with relapsed or refractory T-cell acute lymphoblastic leukemia responded to therapy with donor-derived chimeric antigen receptor T cells, according to results of a phase 1 study.

Nearly 30,000 new cases of diffuse large B-cell lymphoma are diagnosed annually in the United States.

Brexucabtagene autoleucel induced an overall remission rate of greater than 70% among adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a single infusion of the therapy, according to phase 2 study results.

Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent’s manufacturer.

A novel chimeric antigen receptor T-cell therapy showed clinically relevant antitumor activity in nine of 11 younger patients with relapsed or refractory acute myeloid leukemia, according to early data from a phase 1/phase 2 study.

A novel chimeric antigen receptor T-cell therapy induced responses in the first 12 evaluable patients with relapsed or refractory multiple myeloma treated in a phase 1 dose-escalation trial.